Quarterly sales expanded 61%
Revenue is consolidated, not segment-only
Watch: Track profitability
Home / Research / Deepak Nitrite Limited
Quarterly sales expanded 61%
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
Revenue is consolidated, not segment-only
Watch: Track profitability
Phenolics profitability drove operating leverage
Watch: Check durability
Funding and taxes still matter
Watch: Reconcile profit to cash
Growth is not cash conversion
Watch: Monitor operating cash
Deepak Nitrite Limited (DEEPAKNTR) — Q2 and H1 FY2027, quarter ended 30 September 2026. Consolidated issuer presentation and management conference-call evidence.
Decision: WATCH for cash-backed durability of the phenolics recovery and improved Advanced Intermediates utilisation. The company reported its highest-ever consolidated quarterly revenue and EBITDA. Revenue was ₹3,091 crore, up 61% year on year from ₹1,922 crore; EBITDA ₹643 crore, up 187% from ₹224 crore; PBT ₹543 crore versus ₹163 crore; and PAT ₹398 crore versus ₹119 crore. The Q2 EBITDA margin reached 20.8%, versus 11.6% a year earlier. These are the issuer's presented consolidated figures, not a forecast. [S2]
| Consolidated metric, ₹ crore | Q2 FY26 | Q1 FY27 | Q2 FY27 | H1 FY26 | H1 FY27 |
|---|---|---|---|---|---|
| Revenue | 1,922 | 2,592 | 3,091 | 3,836 | 5,682 |
| EBITDA | 224 | 554 | 643 | 438 | 1,197 |
| PBT | 163 | 468 | 543 | 318 | 1,010 |
| PAT | 119 | 345 | 398 | 231 | 743 |
The half-year comparison is just as important: H1 revenue increased 48% to ₹5,682 crore, EBITDA increased 173% to ₹1,197 crore, and PAT increased 221% to ₹743 crore. The presentation gives an H1 EBITDA margin of 21.1% versus 11.3% a year earlier. The company is growing from a particularly weak comparative operating-profit base, so extrapolating the reported percentage gains into a steady-state forecast would be misleading. [S2]
Six investor takeaways
Valuation threshold: The accepted filings do not establish a current share price, diluted share count or comparable enterprise value. A price target would be invented. Investment conviction should instead depend on sustained phenolics spreads and volumes, AI capacity utilisation, post-capex free cash flow and the return earned on the group's new integrated chemical investments.
Deepak Nitrite's Q2 recovery is a powerful example of the difference between revenue expansion and operating leverage. Revenue rose 61%, but EBITDA increased 187% on the company's consolidated presentation. This is encouraging, but the most important question is whether the conditions behind that margin expansion will persist as international chemical supply chains normalise. Management attributed phenolics performance to healthy plant throughput, sourcing agility and supply-chain disruptions that favoured reliable domestic producers. A structural competitive advantage may be emerging, but a temporary disruption can also generate unusually attractive spreads. [S1][S2]
The investment case has two different engines. Phenolics is presently producing the strongest earnings momentum, while Advanced Intermediates is being repositioned toward volume-led recovery and new capacity. These divisions should not be assigned identical margin assumptions. The management call described uneven end-market demand and import-led inventory pressure in AI, despite the stronger consolidated headline. [S1]
Decision tests
The issuer's Q2 financial table reports consolidated revenue ₹3,091 crore, EBITDA ₹643 crore, PBT ₹543 crore and PAT ₹398 crore. Compared with Q1 FY27, these were respectively ₹2,592 crore, ₹554 crore, ₹468 crore and ₹345 crore. Q2 revenue growth was therefore approximately 19% sequentially, EBITDA approximately 16%, and PAT approximately 15%, consistent with the company's rounded published growth percentages. The comparison shows that sequential EBITDA did not outgrow sales even though year-on-year operating leverage was exceptional. [S2]
The presentation shows Q2 FY26 revenue ₹1,922 crore, EBITDA ₹224 crore, PBT ₹163 crore and PAT ₹119 crore. On those values, the EBITDA margin improved from approximately 11.7% to 20.8%; the company reports 11.6% for the prior period, a small difference arising from rounded presentation figures. It would be inaccurate to imply the same improvement occurred every quarter. Q1 FY27's EBITDA margin from rounded figures was approximately 21.4%, slightly higher than Q2. [S2]
The H1 numbers are revenue ₹5,682 crore, EBITDA ₹1,197 crore, PBT ₹1,010 crore and PAT ₹743 crore. The corresponding H1 FY26 values were ₹3,836 crore, ₹438 crore, ₹318 crore and ₹231 crore. The H1 margin comparison—21.1% versus 11.3%—shows that the recovery spans more than a single quarter, although it still coincides with a volatile global feedstock environment. [S2]
The selected presentation provides a headline consolidated PBT and PAT table, but the excerpts used here do not support a full exceptional-item and tax bridge. Consequently these values are reported as the company's published consolidated presentation figures, not reclassified as adjusted or normalised profit. Neither the EBITDA-to-PAT spread nor a margin ratio can substitute for a statutory cash-flow statement. A responsible investor should request actual operating cash flow and cash taxes when judging earnings quality.
Financial interpretation
Phenolics was the decisive contributor to quarterly operating improvement. Its revenue increased to ₹2,291 crore from ₹1,333 crore in Q2 FY26; its EBIT rose to ₹515 crore from ₹145 crore. The segment's implied EBIT-to-revenue ratio on the rounded presentation figures is about 22.5%, compared with 10.9% a year earlier. This is a segment EBIT calculation, not consolidated EBITDA margin. [S2]
Management said the phenolics chain maintained high throughput, with several assets operating at or above rated capacity. The company described import disruptions and customer preference for assured domestic supply as factors improving competitive positioning. This explains why a high utilisation level and a favourable market spread can reinforce one another. The risk is symmetrical: when global imports normalise or feedstock costs change, pricing and contribution margins may not remain at this unusually strong level. [S1]
Advanced Intermediates reported Q2 revenue ₹811 crore against ₹588 crore a year earlier, approximately 38% growth, while EBIT was ₹49 crore versus ₹23 crore. Its derived EBIT margin is about 6.0% against 3.9% a year earlier. Although profitability improved, the division is much less profitable than Phenolics on this measure. The issuer presentation also shows AI Q1 revenue around ₹804 crore and EBIT ₹67 crore, so Q2 AI EBIT declined sequentially despite broadly stable revenue. [S1][S2]
The call explained that earlier strong domestic demand prompted customers to procure imported material at elevated raw-material prices; some imports arrived in July and reduced domestic plant utilisation. Management is emphasising integration from ammonia to amines and from propylene to polycarbonate, along with new product commercialisation. These investments may strengthen cost competitiveness, but the near-term economics depend on volumes and product pricing. [S1]
The Q2 revenue mix shown in the presentation was approximately 88% domestic and 12% export. That highlights exposure to domestic industrial demand and import substitution, but it should not be mistaken for an immunity to global feedstock or finished-product pricing. [S2]
Segment watchpoints
The earnings call described the expansion programme as moving from construction toward commissioning and commercialisation in selected product lines. Management expects new assets to contribute incremental revenue and efficiencies as utilisation stabilises. This is a credible operational roadmap, but the timing of customer qualifications, ramp-up losses and final returns cannot be inferred from an announcement of mechanical completion. [S1]
The integrated polycarbonate initiative at Dahej remains an important strategic project. Management described progress on the site and the dismantling and relocation activities in Germany, alongside customer qualification work for polycarbonate compounds. This is a longer-cycle advanced-materials opportunity; no current-quarter revenue should be attributed to future capacity without evidence of actual sales. [S1]
The call's analyst questions tested the AI margin recovery rather than merely celebrating the group record. One analyst referenced a completed approximately ₹300 crore fluorination capex and asked how that asset and nitration benefits would change profitability. Management expected Q3 AI EBIT percentage to lie between Q1 and Q2, closer to Q1, while newly added assets should contribute over time. This is a forward-looking operating expectation, not a booked result or an independently verified capex cash outflow. [S1]
Management also discussed new product and downstream integration opportunities. Investors should distinguish three stages: technical completion, qualified customer demand and commercially profitable throughput. Only the third stage establishes that the investment is earning an economic return. A project that is technically ready can still require working capital, depreciation and financing before revenue reaches the intended scale.
Execution checklist
Management reported consolidated net worth of ₹6,521 crore at September 2026. Consolidated net debt was ₹1,657 crore, versus ₹1,676 crore at the preceding quarter-end. The net debt-to-equity ratio improved from 0.27x to 0.25x. These are management's stated consolidated measures and should not be combined with any standalone debt number. [S1]
The net cash conversion cycle shortened to 53 days from 57 days in Q1. Management credited inventory efficiency and receivables discipline. A four-day improvement is operationally encouraging, but without the actual quarterly cash-flow statement it is not possible to convert that change into a verified cash release or free cash flow. The improvement also must be tested against the inventory demands of newly commissioned capacity. [S1]
The expansion programme is capital intensive. The approximately ₹300 crore fluorination capex mentioned in analyst Q&A is an individual project reference, not a full consolidated cash capex figure. The selected evidence does not provide a reliable complete group cash capex bridge, depreciation schedule or project-level invested capital. Therefore this report does not claim a fabricated project payback period. [S1]
The capital allocation challenge is to sustain the profitable phenolics base while funding AI and downstream products without allowing leverage to rise faster than operating cash generation. Management said financing arrangements for its investments were in place and that it was monitoring project expenditure, funding requirements and cash flow. That provides a funding framework but not a guaranteed cash return. [S1]
Cash and leverage tests
Bull case — phenolics strength persists and AI catches up. Phenolics continues to benefit from high utilisation and reliable supply, while AI plants regain utilisation and newly commissioned assets lift segment EBIT. The group converts EBITDA into cash, reduces its working-capital cycle further and funds growth without material leverage deterioration. This case would be confirmed by durable segment EBIT, operating cash flow and new-project revenue rather than management commentary alone. [S1][S2]
Base case — record earnings normalise but capacity contributes. Phenolics spreads moderate from the unusually favourable Q2 environment while AI volume growth and project ramp-up gradually offset the decline. Revenue expands, but consolidated margins fluctuate around feedstock cycles and new-facility operating costs. Debt remains manageable, though capital investment limits near-term free cash flow. This is a scenario, not a numerical forecast.
Bear case — temporary spreads reverse before new assets mature. Import competition and lower phenolics pricing compress segment EBIT, AI remains exposed to underutilisation, and newly commissioned capacity adds depreciation and working-capital needs without adequate contribution. The strong Q2 growth rates prove cyclical rather than durable. Financing costs and slower cash conversion would then constrain returns even if headline revenue stays high.
Falsifiers
These cases deliberately omit invented revenue forecasts, price targets and terminal multiples.
Action: WATCH; demand evidence that the record quarter becomes sustainable cash-generating performance. Deepak Nitrite has delivered impressive consolidated profit recovery. Yet its current value depends on two tests: whether phenolics profitability survives a more normal global market, and whether Advanced Intermediates earns acceptable returns on the expansion programme.
| Item | Latest supported reference | Next-quarter question |
|---|---|---|
| Consolidated Q2 revenue | ₹3,091 crore | Does growth remain broad-based? |
| Consolidated Q2 EBITDA | ₹643 crore | Does margin remain resilient? |
| Consolidated Q2 PAT | ₹398 crore | How does PAT convert to cash? |
| H1 revenue / EBITDA | ₹5,682 crore / ₹1,197 crore | Is operating leverage sustainable? |
| Phenolics Q2 revenue / EBIT | ₹2,291 crore / ₹515 crore | Are spreads and throughput holding? |
| AI Q2 revenue / EBIT | ₹811 crore / ₹49 crore | Does utilisation recover? |
| Consolidated net debt | ₹1,657 crore | Are new projects self-funding? |
| Net debt-to-equity | 0.25x | Is leverage still controlled? |
| Net cash conversion cycle | 53 days | Does inventory discipline continue? |
| Fluorination project | Analyst-cited ~₹300 crore capex | Is commercial EBIT contribution visible? |
| Polycarbonate initiative | Dahej and German relocation progress | Are qualification and commissioning milestones met? |
Questions for the next results call
Evidence limitations specific to this decision: The accepted presentation and call establish consolidated operating results, segment revenue and EBIT, net debt and conversion-cycle commentary. They do not establish a full project-by-project return-on-capital bridge, a complete cash capex and free-cash-flow statement, current market valuation or a statutory-versus-adjusted profit reconciliation sufficient for a precise target price. These gaps are left unfilled rather than replaced by assumptions.
All rupee amounts are in crore. Consolidated EBITDA and PAT, segment EBIT, management commentary and derived margins are separately identified.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=17448e49-e6d5-4616-be82-86a78e83bb8c.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.